Supplementary Figure S5C shows the score of the Olaparib identified from the CMap database. Additionally, the mechanism of action analysis revealed that Olaparib is a PARP inhibitor, providing new insights into the drug’s therapeutic mechanism (Supplementary Figure S5D). Furthermore, Olaparib possesses favorable ADMET properties (Figure 13C), supporting its potential as a drug for CRC. This evidence concerns the gene PARP1 and colorectal carcinoma.